WHATS BETTER MEDS OR GENE THERAPIES ???
Dec 14, 2008
Hi Dr Bob, l love your work, l am recently infected with HIV, but not on meds cd4 375 and virol load 84,000, l will be on meds soon but looking for a new treatment,
Can you explain to me the difference between HIV drug and gene therapies??? Which is more effective for those living with HIV? And are they both available in the U.S. or outside of the USA ??? thank you for your time steven
Response from Dr. Frascino
Gene therapies for HIV/AIDS are still very much experimental and not anywhere near ready for primetime. Your best option is a carefully constructed regimen of antiretroviral medications. Your HIV specialist should work closely with you regarding your therapeutic options, including currently enrolling clinical trials of experimental therapies. I'll reprint some information about gene therapy below.
genetically engineer immune cells into potent weapons for battling HIV (CTL, GENE THERAPY) Mar 7, 2008
I would love to know what you think about this.................Einstein researchers genetically engineer immune cells into potent weapons for battling HIV March 4, 2008 (Bronx, NY) By outfitting immune-system killer cells with a new pair of genes, scientists at the Albert Einstein College of Medicine of Yeshiva University transformed them into potent weapons that destroy cells infected with HIV, the virus that causes AIDS. Their novel strategy of genetically engineering immune cells to redirect their infection-fighting ability toward killing HIV-infected cells could lead to an entirely new approach for combating AIDS and other viral diseases. The findings appear in the March issue of the Journal of Virology.
After someone is infected with HIV, a subgroup of their immune cells known as CD8 cytotoxic T lymphocytes, or CTLs, recognize cells infected with HIV and kill them before they become HIV-producing factories. This CTL activity initially keeps the infection in check.
But thenlargely because these CTLs may not bind tightly enough to the infected cells or because HIV mutates so rapidlythe virus typically evades and ultimately overpowers the immune system, leading to an increase in viral load that, in the absence of drug therapy, results in AIDS. However, a very small percentage of HIV-infected people known as elite controllers manage to suppress HIV infection for many years.
Certain of the CTLs of elite controllers may be genetically equipped to bind tightly to HIV-infected cells and destroy them and thereby suppress the infection indefinitely, says Dr. Harris Goldstein, senior author of the study and Director of the Einstein/Montefiore Center for AIDS Research. Our idea, says Dr. Goldstein, was first to identify the elite controllers super CTLs and to isolate the genes that enable these cells to bind tightly to HIV-infected cells and kill them efficiently; then we would transfer these genes into CTLs that do not recognize HIV-infected cells and convert them into potent killers of those cells.
After infecting a cell, HIV instructs it to make viral proteins. Tiny bits of these proteins, known as peptides, are displayed on the surface of the infected cellthe cells way of signaling the immune system that it is infected. Detecting virus-infected cells so they can then be eliminated is the job of CTLs and the protein molecules, known as T-cell receptors, that jut from their surface.
If a CTLs T-cell receptor has the right amino acid sequence, it will recognize the HIV peptide on the infected cell as foreign--prompting the CTL to multiply and attack the infected cell. But all too often, this battle between activated CTLs and HIV-infected cells ends badly. Why, then, are super CTLs of elite controllers so effective in killing HIV-infected cells"
The explanation, the Einstein researchers postulated, is that these CTLs express T-cell receptors that either have a knack for recognizing viral peptides that tend not to mutate, or they bind extremely tightly to HIV-infected cells, enabling the elite controllers to keep their HIV infections under control.
A CTLs T-cell receptor, which is as unique for each CTL as a persons fingerprint, consists of two chains, alpha and beta. To obtain the blueprint for making exceptionally potent HIV-specific T-cell receptors, the researchers isolated the genes that code for each of the two chains from the potent HIV-specific CTL. Then, as a way to efficiently insert both genes into nave CTLs (from people not infected with HIV), they developed an efficient delivery system in which the genes were combined and packaged inside a special type of virus, called a lentivirus. The lentiviruses then inserted these genes into the chromosomes of nave CTLs obtained from a nave donors blood and reprogrammed them into potent HIV-specific CTLs.
We demonstrated that these genetically reprogrammed CTLs have very strong activity in terms of killing HIV-infected cells in both test tubes and an animal model, says Dr. Goldstein. In some of the animal studies, for example, the researchers injected mice with both HIV-infected human cells and with reprogrammed nave CTLs into which the HIV-recognizing T-cell receptor genes had been inserted using the lentiviral delivery system. One week later, when the researchers looked for HIV-infected human cells in the animals, they found that the infected cells had virtually been eliminated.
Dr. Goldstein notes that this study was done using genes for just a single CTL T-cell receptor. To make this strategy even more effective, were now in the process of isolating a cocktail of CTL receptor genes that are specific for many different HIV peptidesan approach analogous to todays combination drug therapy for treating HIV infection, says Dr. Goldstein. Ultimately, wed like to remove CTLs from patients, convert them into potent HIV-specific CTLs by inserting a variety of HIV-specific CTL receptor genes, and then re-infuse these fresh, genetically reprogrammed CTLs back into patients. By reinforcing the immune system in this way, we hope to turn the tide of battle against HIV in favor of people infected with the virus.
Response from Dr. Frascino
This is extremely interesting and important work. As an immunologist, I have advocated immune-based therapies for HIV treatment and, ultimately, cure since the early days of the epidemic. It's becoming clearer that despite truly remarkable progress in the development of antiretroviral drugs, ultimately we need something else to help us reach the holy grail of "cure!" Immune-based therapy holds the most promise. The report you cited involves gene therapy, which is perhaps the most promising and, unfortunately, the most challenging type of immune-based therapy. The immune system is exquisitely balanced and phenomenally complex. Every time we tinker with one small aspect of it unintended consequences are set off elsewhere in the system. To provide an analogy, using our current scientific tools and techniques to genetically fix a problem involving the immune system is a bit like using only a sledgehammer to tune up your Maserati's engine. No doubt we are making great strides in genetic engineering and in achieving a better understanding of the immune-based pathophysiology of HIV. I too believe the elite controllers may well hold the key to ultimately unlocking this mystery. The research you quote is fascinating and certainly worth pursuing, but don't look for genetically engineered CTLs to show up on the pharmacy shelves at your local Piggly Wiggly anytime soon. This is very preliminary stuff and has only been investigated in "Mickey and Minnie." When it comes to genetics and illness, the significant differences "of mice and men" are well known. Just ask Steinbeck!
We'll all be following this CTL story and promise to keep you updated as further information becomes available.
Get Email Notifications When This Forum Updates or Subscribe With RSS
This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.
Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither TheBody.com nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.